Iovance Biotherapeutics to Present Data at Upcoming ESMO 2017 Congress on Tumor-Infiltrating Lymphocyte Treatment for Lymphom...
August 31 2017 - 4:27PM
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology
company developing novel cancer immunotherapies based on
tumor-infiltrating lymphocyte (TIL) technology, today announced
release of an abstract that will be presented in a poster at the
upcoming European Society for Medical Oncology (ESMO) 2017 Congress
from September 8 -12 in Madrid, Spain. Abstracts are available to
the public online on the ESMO website: www.esmo.org. Details
of the poster are as follows:
- Title: Phenotypic and functional
characterization of tumor infiltrating lymphocytes (TIL) grown from
non-hodgkin lymphoma tumors: Implications for the development of
novel therapies for lymphoma
- Author: L. Karyampudi et al.
- Date/Time: Saturday, September 9, 2017 from
13:15-14:15 local time
- Location: Hall 8
- Abstract Number: 1017P
“As we explore potential utilization of TIL in treatment of
multiple cancer types, we present data at ESMO that demonstrate the
ability to produce TIL from lymphoma that have similar
functionality as TIL generated from melanoma, giving us reason to
further explore the potential of our TIL cell therapy for lymphoma
patients in the future,” said Dr. Maria Fardis, PhD, MBA, Chief
Executive Officer of Iovance Biotherapeutics. “Leveraging our
experience in TIL generation from solid tumors to blood-born
cancers is a natural extension of our learnings to date. We are
exploring potential collaborations with lymphoma experts to
supplement our research efforts. The data to be presented at ESMO
is indicative of our efforts in becoming a leader in TIL treatment
for a variety of tumor types.”
About the European Society for Medical Oncology
(ESMO)ESMO is the leading professional organisation for
medical oncology. With 16,000 members representing oncology
professionals from over 130 countries worldwide, ESMO is the
society of reference for oncology education and information.
About Iovance Biotherapeutics, Inc. Iovance
Biotherapeutics, Inc. is a clinical-stage biotechnology company
focused on the development of cancer immunotherapy products for the
treatment of various cancers. The Company's lead product candidate
is an adoptive cell therapy using tumor-infiltrating lymphocyte
(TIL) technology being investigated for the treatment of patients
with metastatic melanoma, recurrent and/or metastatic squamous cell
carcinoma of the head and neck and recurrent and metastatic or
persistent cervical cancer. For more information, please
visit http://www.iovance.com.
Forward-Looking Statements Certain matters
discussed in this press release are “forward-looking statements”.
The Company may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. The
forward-looking statements include risks and uncertainties,
relating to the Company’s ability to advance its global development
programs and the efficacy of its immune-oncology TIL
therapies. A further list and description of the Company’s
risks, uncertainties and other factors can be found in the
Company’s most recent Annual Report on Form 10-K and the Company's
subsequent filings with the Securities and Exchange Commission.
Copies of these filings are available online at www.sec.gov or
www.iovance.com. The forward-looking statements are made only as of
the date of this press release and the Company undertakes no
obligation to publicly update such forward-looking statements to
reflect subsequent events or circumstance.
Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah@sternir.com
Media Relations Contact:
Evan Smith/Kotaro Yoshida
FTI Consulting
212-850-5622/212-850-5690
evan.smith@fticonsulting.com
kotaro.yoshida@fticonsulting.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Sep 2023 to Sep 2024